BiotechTube

RP2 + Pegfilgrastim + Filgrastim

Phase 2Recruiting
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Gastric Adenocarcinoma

Conditions

Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma

Trial Timeline

Apr 1, 2026 → Nov 1, 2029

NCT ID
NCT07059611

About RP2 + Pegfilgrastim + Filgrastim

RP2 + Pegfilgrastim + Filgrastim is a phase 2 stage product being developed by Replimune for Gastric Adenocarcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07059611. Target conditions include Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT07059611Phase 2Recruiting

Competing Products

20 competing products in Gastric Adenocarcinoma

See all competitors
ProductCompanyStageHype Score
pemetrexed + cisplatinEli LillyPhase 1/2
41
InfigratinibLianBioPhase 2
44
InfigratinibLianBioPhase 2
44
Ramucirumab + MEDI4736Eli LillyPhase 1
33
RamucirumabEli LillyPhase 2
52
Trastuzumab + Capecitabine + CisplatinCelltrionPhase 2
52
Trastuzumab + Fluorouracil + Cisplatin + CapecitabineChugai PharmaceuticalPhase 3
77
Fluorouracil (5-FU) + Capecitabine + Durvalumab + Oxaliplatin + Trastuzumab + Trastuzumab deruxtecan + Cisplatin + Pembrolizumab + Volrustomig + RilvegostomigDaiichi SankyoPhase 2
52
Trastuzumab DeruxtecanDaiichi SankyoPhase 2
52
Trastuzumab deruxtecan + Ramucirumab + PaclitaxelDaiichi SankyoPhase 3
77
Trastuzumab deruxtecanDaiichi SankyoPre-clinical
23
Trastuzumab Deruxtecan (T-DXd) monotherapy + T-DXd, Durvalumab and Capecitabine CombinationDaiichi SankyoPhase 2
52
Trastuzumab deruxtecan + BevacizumabDaiichi SankyoPhase 2
52
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
Trastuzumab deruxtecan (T-DXd)Daiichi SankyoPre-clinical
23
DS-8201aDaiichi SankyoPhase 1
33
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
Irinotecan + NimotuzumabDaiichi SankyoPhase 3
77
Trastuzumab Deruxtecan + pembrolizumab + Trastuzumab + ChemotherapyDaiichi SankyoPhase 3
77
Trastuzumab deruxtecan + 5FU/LV + Trastuzumab deruxtecan + FLODaiichi SankyoPhase 1/2
41

Other Products from Replimune

Vusolimogene Oderparepvec + Nivolumab + Nivolumab + Relatlimab + Pembrolizumab + Single-agent chemotherapyPhase 3
69
RP2 + Ipilimumab + NivolumabPhase 2/3
57
RP2 + Bevacizumab + Atezolizumab + Durvalumab + RP2 MonotherapyPhase 2
44
Vusolimogene Oderparepvec (VO) + PembrolizumabPhase 2
44
RP2 InjectionPhase 2
44